Full Breakdown
WHO Signals Mixed Progress in DRC Ebola Outbreak
By Drooid · · How we work
Core Event: WHO Highlights Gains and Ongoing Threats
On September 16 2026, WHO Director-General Tedros Adhanom Ghebreyesus told reporters in Geneva that transmission is declining in Ituri province, while the epidemic continues to expand in other regions of the Democratic Republic of Congo (DRC). He described the situation as “many outbreaks in many places” and warned that the outbreak remains far from over.
Background & Context
The DRC declared its 17th Ebola outbreak in mid-May 2026. The strain is the Bundibugyo species, for which no proven cure exists. The outbreak has spread to seven northern and eastern provinces, adding to existing insecurity and displacement.
Data & Statistics
- Confirmed cases across the seven provinces total over 7,200 (latest reports).
- Deaths are reported at about 3,500.
- In Ituri, roughly 300 new cases and 160 deaths were recorded in the week before September 16, accounting for about half of the national total.
- North Kivu’s weekly cases have nearly doubled from about 100 to more than 200.
- Over 3,000 frontline health workers have received the Merck-produced Ervebo vaccine; an observational study of its effectiveness will start within days.
Official Statements & Responses
Tedros noted that South Kivu has reported no new cases since May and that the outbreak remains largely confined to northeastern DRC, aside from a brief spill-over into Uganda that was quickly contained.
Maria Van Kerkhove, WHO’s acting director of epidemic and pandemic threat management, called for “cautious optimism” but stressed that “the key indicators are not yet improving as they must.” She highlighted ongoing surveillance, expanded contact-tracing, and an upcoming Phase 3 vaccine trial that will evaluate Ervebo alongside Bundibugyo-specific candidates from Moderna and the University of Oxford.
Meg Doherty, WHO’s director of science, research, evidence and quality for health, announced that an observational trial involving vaccinated frontline workers will begin within the week, with a randomized Phase 3 trial expected shortly thereafter.
Why It Matters / Impact
The outbreak is the second-largest Ebola event on record, after the 2014-2016 West African epidemic. Continued spread threatens to worsen humanitarian crises, including hunger, reduced health-facility attendance, and interruptions to HIV treatment and maternal health services. Successful vaccine trials could provide the first efficacy data for Bundibugyo-targeted vaccines, informing future responses across Africa.
Conflicting Reports & Gaps
- Case counts: France 24 cites “more than 7,000 cases” as of September 11, while Al Jazeera, AP, Statnews, AA, NZ Herald, and Gazette report “over 7,200 cases.”
- Death toll: Figures range from “more than 3,500 deaths” to “3,510 deaths.”
- Vaccination effectiveness: WHO acknowledges that Ervebo’s protection against the Bundibugyo strain is “not known,” pending observational and trial results.
These discrepancies reflect differences in reporting dates, surveillance scope, and the evolving nature of the outbreak.
Verbatim Quotes
- “We are now starting to see encouraging signs that we are gaining ground. In the most affected parts of Ituri province, transmission is going down,” — Tedros
- “But make no mistake, the epidemic continues to grow and continues to kill,” — Tedros
- “The key indicators are not yet improving as they must,” — Tedros
*All statements and figures are attributed to the officials or organizations that provided them.*